Table 1.
Baseline characteristics between twice-weekly and once-weekly bortezomib.
| ALL | Twice-weekly | Once-weekly | p-value | |
|---|---|---|---|---|
| N = 2497 | N = 910 | N = 1587 | ||
| Age at index | 62.0 [56.0;67.0] | 62.0 [57.0;67.0] | 62.0 [56.0;67.0] | 0.774 |
| Gender | 0.478 | |||
| Male | 1383 (55.4%) | 513 (56.4%) | 870 (54.8%) | |
| Female | 1114 (44.6%) | 397 (43.6%) | 717 (45.2%) | |
| Race/ethnicity | <0.001 | |||
| Non-Latinx White | 1242 (49.7%) | 467 (51.3%) | 775 (48.8%) | |
| Non-Latinx Black | 552 (22.1%) | 208 (22.9%) | 344 (21.7%) | |
| Hispanic or Latinx | 212 (8.5%) | 102 (11.2%) | 110 (6.9%) | |
| Non-Latinx Asian | 58 (2.3%) | 14 (1.5%) | 44 (2.8%) | |
| Other | 117 (7.1%) | 52 (5.7%) | 125 (7.9%) | |
| Unknown | 256 (10.3%) | 67 (7.4%) | 189 (11.9%) | |
| Practice type | 0.040 | |||
| Community | 1925 (77.1%) | 723 (79.5%) | 1202 (75.7%) | |
| Academic | 451 (18.1%) | 154 (16.9%) | 297 (18.7%) | |
| Both | 121 (4.8%) | 33 (3.6%) | 88 (5.5%) | |
| Year of diagnosis | 2019 [2018;2021] | 2019 [2018;2021] | 2020 [2018;2021] | <0.001 |
| ECOG PS at 1L | 0.016 | |||
| 0 | 839 (33.6%) | 334 (36.7%) | 505 (31.8%) | |
| 1 | 782 (31.3%) | 288 (31.6%) | 494 (31.1%) | |
| ≥2 | 344 (13.8%) | 105 (11.5%) | 239 (15.1%) | |
| Unknown | 532 (21.3%) | 183 (20.1%) | 349 (22.0%) | |
| ISS stage | 0.180 | |||
| Stage I | 685 (27.4%) | 265 (29.1%) | 420 (26.5%) | |
| Stage II | 516 (20.7%) | 181 (19.9%) | 335 (21.1%) | |
| Stage II | 533 (21.3%) | 205 (22.5%) | 328 (20.7%) | |
| Unknown | 763 (30.6%) | 259 (28.5%) | 504 (31.8%) | |
| Insurance status at 1L | 0.905 | |||
| Commercial Health Plan | 778 (31.2%) | 276 (30.3%) | 502 (31.6%) | |
| Medicare | 798 (32.0%) | 300 (33.0%) | 498 (31.4%0 | |
| Medicaid | 191 (7.6%) | 67 (7.4%) | 124 (7.8%) | |
| Other payer | 219 (8.8%) | 82 (9.0%) | 137 (8.6%) | |
| Unknown/ uninsured | 511 (20.5%) | 185 (20.3%) | 326 (20.5%) | |
| Number of HRCA | 0.266 | |||
| 0 | 1733 (69.4%) | 619 (68.0%) | 1114 (70.2%) | |
| 1 | 564 (22.6%) | 208 (22.9%) | 356 (22.4%) | |
| ≥2 | 200 (8.0%) | 83 (9.1%) | 117 (7.4%) | |
| Serum creatinine level at 1L | 0.802 | |||
| ≤1.2 mg/dL | 1216 (48.7%) | 434 (47.7%) | 782 (49.3%) | |
| 1.3–2.9 mg/dL | 494 (19.8%) | 183 (20.1%) | 311 (19.6%) | |
| ≥3 mg/dL | 202 (8.1%) | 79 (8.7%) | 123 (7.8%) | |
| Unknown | 585 (23.4%) | 214 (23.5%) | 371 (23.4%) | |
| Hemoglobin level (g/dL) | 10.7 [9.1;12.3] | 10.6 [9.0;12.3] | 10.7 [9.2; 12.3] | 0.385 |
| Concurrent therapy at 1L | ||||
| Bortezomib only | 27 (1.1%) | 9 (1.0%) | 18 (1.1%) | |
| CyBorD | 305 (12.2%) | 74 (8.1%) | 231 (14.6%) | |
| D-Vd | 41 (1.6%) | 8 (0.9%) | 33 (2.1%) | |
| D-VRd | 276 (11.1%) | 83 (9.1%) | 193 (12.2%) | |
| Other | 5 (0.2%) | < 5 | < 5 | |
| Vd | 130 (5.2%) | 54 (5.9%) | 76 (4.8%) | |
| VRd | 1713 (68.6%) | 681 (74.8%) | 1032 (65.0%) | |
| Bortezomib starting routes at 1L | <0.001 | |||
| Subcutaneous | 2368 (94.9%) | 841 (92.4%) | 1527 (96.3%) | |
| Intravenous | 128 (5.1%) | 69 (7.6%) | 59 (3.7%) | |
| Any neuropathy diagnosis or medication for severe neuropathy | 610 (24.4%) | 316 (34.7%) | 294 (18.5%) | <0.001 |
| Drug-induced neuropathy diagnosis | 134 (5.4%) | 87 (9.6%) | 47 (3.0%) | <0.001 |
| Other neuropathy diagnosis | 141 (5.6%) | 78 (8.6%) | 63 (4.0%) | <0.001 |
| Medication for severe neuropathy | 506 (20.3%) | 272 (29.9%) | 234 (14.7%) | <0.001 |
ECOG Eastern Cooperative Oncology Group, PS performance status, HRCA high-risk cytogenetic abnormality, CyBorD cyclophosphamide-bortezomib-dexamethasone, D-Vd daratumumab-bortezomib-dexamethasone, D-VRd daratumumab-bortezomib-lenalidomide-dexamethasone, Vd: bortezomib-dexamethasone, VRd bortezomib-lenalidomide-dexamethasone.